$5.11 Million in Sales Expected for Valeritas Holdings, Inc. (NASDAQ:VLRX) This Quarter
Analysts predict that Valeritas Holdings, Inc. (NASDAQ:VLRX) will announce $5.11 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Valeritas Holdings’ earnings. The highest sales estimate is $5.29 million and the lowest is $5.00 million. Valeritas Holdings posted sales of $4.89 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.5%. The business is scheduled to announce its next quarterly earnings report on Wednesday, August 9th.
According to Zacks, analysts expect that Valeritas Holdings will report full year sales of $5.11 million for the current financial year, with estimates ranging from $20.95 million to $22.43 million. For the next fiscal year, analysts anticipate that the company will report sales of $28.15 million per share, with estimates ranging from $26.03 million to $30.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Valeritas Holdings.
Valeritas Holdings (NASDAQ:VLRX) last released its quarterly earnings results on Friday, May 12th. The company reported ($6.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.72) by $4.20. The company had revenue of $4.61 million during the quarter, compared to analyst estimates of $4.64 million.
A number of research firms recently commented on VLRX. B. Riley reiterated a “buy” rating and set a $10.00 price objective on shares of Valeritas Holdings in a research note on Tuesday, April 4th. Wedbush assumed coverage on shares of Valeritas Holdings in a research report on Monday. They issued an “outperform” rating and a $12.00 price target on the stock. ValuEngine lowered shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 11th. Finally, Cowen and Company assumed coverage on shares of Valeritas Holdings in a research report on Monday, April 17th. They issued an “outperform” rating on the stock.
In other Valeritas Holdings news, insider John Edward Timberlake purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were purchased at an average price of $5.14 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the insider now owns 23,037 shares in the company, valued at approximately $118,410.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders acquired 11,500 shares of company stock worth $57,615. 1.20% of the stock is currently owned by company insiders.
An institutional investor recently bought a new position in Valeritas Holdings stock. HighTower Advisors LLC purchased a new stake in Valeritas Holdings, Inc. (NASDAQ:VLRX) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned 1.67% of Valeritas Holdings as of its most recent filing with the SEC. 11.65% of the stock is owned by hedge funds and other institutional investors.
Valeritas Holdings (VLRX) remained flat at $7.00 during midday trading on Friday. The company had a trading volume of 17,350 shares. Valeritas Holdings has a 52-week low of $4.51 and a 52-week high of $52.00. The company’s market cap is $47.89 million. The stock’s 50-day moving average is $5.20 and its 200 day moving average is $18.96.
Valeritas Holdings Company Profile
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related stocks with our FREE daily email newsletter.